Epi-ON Corneal Crosslinking for Ectatic Corneal Diseases
This study is looking at an experimental treatment called Epi-ON corneal crosslinking (CXL) for eye conditions where the cornea (the clear front part of your eye) becomes thin and misshapen, causing blurry vision. CXL involves putting riboflavin (Vitamin B2 eye drops) on your eye and then exposing it to ultraviolet (UVA) light. The goal is to strengthen the cornea and stop the disease from getting worse. This trial compares two different UVA exposure times: 18 minutes versus 24 minutes. We want to see how well each exposure time changes your corneal curvature and vision. You may be able to join if you are at least 8 years old and have conditions like keratoconus or corneal ectasia. The study is currently recruiting 485 participants.
- Study design
- This is an interventional study comparing two different UVA exposure times for Epi-ON corneal crosslinking. It aims to enroll 485 participants.
- What's involved
- The primary outcome measures, corneal curvature and vision, will be assessed from enrollment to the end of treatment at 6 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from enrollment to the end of treatment at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
At a glance
Conditions
Where it's being run
12 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The primary outcome measures for efficacy is corneal curvature, as measured by Kmax with the Pentacam, in the treated eyes and CDVA.From enrollment to the end of treatment at 6 months.
The change in keratometry (Kmax) and corrected visual acuity from baseline will be evaluated at 6 months for all eyes treated. Data will be summarized using descriptive statistics and experimental groups will be compared using nonparametric tests. The change in Kmax and corrected visual acuity from baseline will be evaluated at 6 months.